Ipamorelin
Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R1a) agonist studied for selective GH release without significant impact on cortisol or prolactin in research models — making it a clean tool compound for GH-axis study..
- Vial Size
- 10mg
- Molecular Weight
- 711.85 g/mol
- Half-life
- ~2 hours
- Latest Lot Purity
- 99.36%
Mechanism of Action
Ipamorelin is a pentapeptide ghrelin-receptor (GHS-R1a) agonist studied for selective GH release without significant impact on cortisol or prolactin in research models — making it a clean tool compound for GH-axis study.
Research Context
- Selective GH-secretagogue research
- Ghrelin-receptor pharmacology
- Body-composition study models
- Layered GH-axis protocol design
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Lot NX-022 · Verified at 99.36%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for Ipamorelin.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the Ipamorelin monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 200–300 mcg
- Frequency
- 2–3× daily
- Cycle Length
- 8–12 weeks
- Route
- Subcutaneous
Note ·Selective GH release without cortisol/prolactin spike in models.
Related Compounds
All compounds →
CJC 1295 (without DAC) + IPA
Dual-component GH-axis research blend.
HGH Fragment 176-191
Lipolytic GH fragment for body-composition research models.
Tesamorelin
GHRH analog supporting advanced metabolic and visceral adipose research.
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.